These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36831409)

  • 1. Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma.
    Parent P; Auclin E; Patrikidou A; Mezquita L; Martínez Chanzá N; Dumont C; Rodriguez-Vida A; Llacer C; Lozano R; Ratta R; Merseburger AS; Sternberg CN; Baciarello G; Colomba E; Fuerea A; Besse B; Loriot Y; Lavaud P
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
    Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
    JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer.
    Kazandjian D; Gong Y; Keegan P; Pazdur R; Blumenthal GM
    JAMA Oncol; 2019 Oct; 5(10):1481-1485. PubMed ID: 31343662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer.
    Wang W; Huang Z; Yu Z; Zhuang W; Zheng W; Cai Z; Shi L; Yu X; Lou G; Hong W; Zhang Y; Chen M; Song Z
    Front Oncol; 2020; 10():572853. PubMed ID: 33163403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of the pretreatment lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced hepatocellular carcinoma.
    Sun T; Guo Y; Sun B; Chen L; Ren Y; Zhu L; Zhang L; Liu Y; Zheng C
    Eur J Med Res; 2023 Jul; 28(1):225. PubMed ID: 37408056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score.
    Pierro M; Baldini C; Auclin E; Vincent H; Varga A; Martin Romano P; Vuagnat P; Besse B; Planchard D; Hollebecque A; Champiat S; Marabelle A; Michot JM; Massard C; Mezquita L
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial.
    Hopkins AM; Kichenadasse G; Abuhelwa AY; McKinnon RA; Rowland A; Sorich MJ
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33803256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials.
    Sorich MJ; Rowland A; Karapetis CS; Hopkins AM
    J Thorac Oncol; 2019 Aug; 14(8):1440-1446. PubMed ID: 30999110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of the pretreatment lung immune prognostic index with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors.
    Hou B; Wang P; Liu T; Chen S; Li T; Zhang S; Tao H; Li X; Hu Y
    Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101748. PubMed ID: 34182184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma.
    Carril-Ajuria L; Lavaud P; Dalban C; Negrier S; Gravis G; Motzer RJ; Chevreau C; Tannir NM; Oudard S; McDermott DF; Laguerre B; Hammers HJ; Barthelemy P; Plimack ER; Borchiellini D; Gross-Goupil M; Jiang R; Lee CW; de Silva H; Rini BI; Escudier B; Albigès L
    Eur J Cancer; 2024 Jun; 204():114048. PubMed ID: 38653033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis stratification of cancer patients treated with immune checkpoint inhibitors through lung immune prognostic index: a meta-analysis and systematic review.
    Guo Y; Pan Y; Wan J; Gong B; Li Y; Kan X; Zheng C
    BMC Cancer; 2024 Apr; 24(1):523. PubMed ID: 38664760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors.
    Chen S; Huang Z; Jia W; Tao H; Zhang S; Ma J; Liu Z; Wang J; Wang L; Cui P; Zhang Z; Huang D; Wu Z; Zheng X; Hu Y
    J Hepatocell Carcinoma; 2020; 7():289-299. PubMed ID: 33173757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer.
    Wang Z; Liu H; Zhao J; Chen J; Zhu S; Dai J; Ni Y; Xu N; Zhao F; He B; Zhang X; Liang J; Sun G; Liu Z; Shen P; Zeng H
    Ann Transl Med; 2023 Mar; 11(5):201. PubMed ID: 37007568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment Lung Immune Prognostic Index Is a Prognostic Marker of Chemotherapy and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
    Minami S; Ihara S; Komuta K
    World J Oncol; 2019 Feb; 10(1):35-45. PubMed ID: 30834050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between lung immune prognostic index and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab.
    Nakamura K; Ishiyama Y; Nemoto Y; Ishihara H; Tachibana H; Fukuda H; Shinmura H; Hashimoto Y; Yoshida K; Iizuka J; Ishida H; Kondo T; Takagi T
    Int J Clin Oncol; 2023 Jul; 28(7):913-921. PubMed ID: 37103730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Changes in LIPI Score Predict Immune-Related Adverse Events: A Propensity Score Matched Analysis in Advanced Non-Small Cell Lung Cancer Patients on Immune Checkpoint Blockade.
    Nelli F; Fabbri A; Virtuoso A; Giannarelli D; Giron Berrios JR; Marrucci E; Fiore C; Ruggeri EM
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38275894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value of the Lung Immune Prognostic Index for Metastatic Non-Small Cell Lung Cancer Patients: A Chinese Cohort Study.
    Huang J; Pu H; He J; Tang X
    Int J Gen Med; 2023; 16():881-893. PubMed ID: 36915421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of the Pretreatment Lung Immune Prognostic Index in Advanced Small Cell Lung Cancer Patients Treated With First-Line PD-1/PD-L1 Inhibitors Plus Chemotherapy.
    Li L; Pi C; Yan X; Lu J; Yang X; Wang C; Li X; Zhang S; Zhang Z; Sun Y; Hu Y
    Front Oncol; 2021; 11():697865. PubMed ID: 34692478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
    Riudavets M; Auclin E; Mosteiro M; Dempsey N; Majem M; Prelaj A; López-Castro R; Bosch-Barrera J; Pilotto S; Escalera E; Tagliamento M; Mosquera J; Zalcman G; Aboubakar Nana F; Ponce S; Albarrán-Artahona V; Dal Maso A; Spotti M; Mielgo X; Mussat E; Reyes R; Benítez JC; Lupinacci L; Duchemann B; De Giglio A; Blaquier JB; Audigier-Valette C; Scheffler M; Nadal E; Lopes G; Signorelli D; Garcia-Campelo R; Menis J; Bluthgen V; Campayo M; Recondo G; Besse B; Mezquita L; Planchard D
    Clin Lung Cancer; 2024 May; 25(3):233-243.e8. PubMed ID: 38105153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index.
    Ortega-Franco A; Hodgson C; Raja H; Carter M; Lindsay C; Hughes S; Cove-Smith L; Taylor P; Summers Y; Blackhall F; Califano R
    Target Oncol; 2022 Jul; 17(4):453-465. PubMed ID: 35781861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.